Phaseline

Companies › Celltrion

Celltrion: clinical trials, targets and expected readouts

5 active drug programs in 5 registered trials: 4 Phase 3, 1 Phase 1; Oncology, Neurology, Other, Immunology; next expected readout Feb 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
CT-P51
PD-1 inhibitor
PDCD1Phase 3Non Squamous Non Small Cell Lung CancerFeb 2027
Ocrelizumab (P53)
B-lymphocyte antigen CD20 binding agent
MS4A1Phase 3Relapsing-remitting Multiple SclerosisFeb 2027
CT-P44
anti-CD38 monoclonal antibody
CD38Phase 3Refractory or Relapsed Multiple MyelomaMar 2027
Secukinumab (P55)
Interleukin 17A inhibitor
IL17APhase 3Plaque Psoriasis–
CT-P52
IL-17A inhibitor biosimilar
IL17APhase 1Healthy Participants–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06630559Secukinumab (P55)Phase 3Plaque PsoriasisImmunologyFeb 2026
NCT07200986CT-P52Phase 1Healthy ParticipantsOtherMar 2026
NCT05906992Ocrelizumab (P53)Phase 3Relapsing-remitting Multiple SclerosisNeurologyFeb 2027
NCT06939595CT-P51Phase 3Non Squamous Non Small Cell Lung CancerOncologyFeb 2027
NCT06952478CT-P44Phase 3Refractory or Relapsed Multiple MyelomaOncologyMar 2027

From the company's SEC filings

Complete response letters from FDA

Targets

IL17A (2) MS4A1 (1) PDCD1 (1) CD38 (1)

Companies with the same targets

Roche Akeso Biocad AstraZeneca Shanghai Henlius Biotech Novartis Regeneron Pharmaceuticals Sichuan Baili Pharmaceutical Innovent Biologics (Suzhou) Johnson & Johnson (Janssen)

Companies built like this

R-Pharm Biocad RemeGen Sinocelltech Taizhou Mabtech Pharmaceutical

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.